Literature DB >> 7199382

Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing.

F A Levi, W J Hrushesky, C H Blomquist, D J Lakatua, E Haus, F Halberg, B J Kennedy.   

Abstract

A prominent circadian rhythm in the nephrotoxicity of a therapeutic dose of cis-diamminedichloroplatinum (cisplatin) is demonstrated in female Fischer rats. Rats were randomized to receive two doses of either cisplatin or 0.9% NaCl solution 14 days apart at the times of either high or low values in their circadian rhythm of urinary volume. Toxicity was assessed by measuring changes in body weight and changes in the 24-hr means of urinary volume, blood urea nitrogen, and urinary beta-N-acetylglucosaminidase (NAG) activity. Toxicity was least in rats which received the drug near the circadian maximum of urinary volume. Conversely, rats which received the same dose of drug near the circadian minimum of urinary volume lost more weight and exhibited a 2-fold increase in the 24-hr mean of urinary volume, a 3-fold rise in the 24-hr mean of blood urea nitrogen, and a 5-fold increase in the 24-hr mean of urinary NAG activity. A positive correlation between urinary NAG at the time of cisplatin administration and the extent of cisplatin nephrotoxicity was demonstrated (p less than 0.02). A correlation also was found between tissue NAG concentration and tissue uptake of cisplatin (p less than 0.001). A marked circadian rhythm of NAG activity in proximal tubular cells may contribute to the prominent circadian rhythm in murine renal tolerance for cisplatin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7199382

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve.

Authors:  B Hecquet; M Sucche
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

Review 2.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

4.  Chronokinetic study of netilmicin in man.

Authors:  F Lucht; S Tigaud; G Esposito; J Cougnard; M P Fargier; D Peyramond; J L Bertrand
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Circadian Rhythms, Disease and Chronotherapy.

Authors:  Yool Lee; Jeffrey M Field; Amita Sehgal
Journal:  J Biol Rhythms       Date:  2021-09-22       Impact factor: 3.649

6.  DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients.

Authors:  R Smaaland; J F Abrahamsen; A M Svardal; K Lote; P M Ueland
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 7.  Circadian Variation in Efficacy of Medications.

Authors:  James C Walton; William H Walker; Jacob R Bumgarner; O Hecmarie Meléndez-Fernández; Jennifer A Liu; Heather L Hughes; Alexis L Kaper; Randy J Nelson
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.903

8.  Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma.

Authors:  Galina Kireeva; Ekaterina Gubareva; Mikhail Maydin; Vladislav Osetnik; Stepan Kruglov; Andrey Panchenko; Anastasia Dorofeeva; Margarita Tyndyk; Elena Fedoros; Vladimir Anisimov
Journal:  Onco Targets Ther       Date:  2021-05-24       Impact factor: 4.147

9.  Influence of dosing times on cisplatin-induced peripheral neuropathy in rats.

Authors:  Yoshihiro Seto; Fumiyasu Okazaki; Keiji Horikawa; Jing Zhang; Hitoshi Sasaki; Hideto To
Journal:  BMC Cancer       Date:  2016-09-27       Impact factor: 4.430

10.  The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models.

Authors:  Panshak P Dakup; Kenneth I Porter; Alexander A Little; Rajendra P Gajula; Hui Zhang; Elena Skornyakov; Michael G Kemp; Hans P A Van Dongen; Shobhan Gaddameedhi
Journal:  Oncotarget       Date:  2018-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.